REGISTERED NUMBER: 08483710 (England and Wales)

Unaudited Financial Statements

for the Year Ended 30 April 2026

for

MOLECULAR ONCOLOGY LIMITED

Page

Balance Sheet

1

FIXED ASSETS

85,162

49,224

CURRENT ASSETS

544,213

504,808

CREDITORS

Amounts falling due within one year

(11,887

)

(11,103

)

NET CURRENT ASSETS

532,326

493,705

TOTAL ASSETS LESS CURRENT LIABILITIES

617,488

542,929

CAPITAL AND RESERVES

617,488

542,929

NOTES TO THE FINANCIAL STATEMENTS

1.	STATUTORY INFORMATION

Molecular Oncology Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

08483710

Registered office:

2 St Mary's Road

Tonbridge

Kent

TN9 2LB

2.	AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was 4 (2025 - 3 ) .

3.	DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the year ended 30 April 2026 and the period ended 30 April 2025:

2026

2025

£

£

Dr R C Swanton

Balance outstanding at start of year

323,762

321,331

Amounts advanced

23,741

16,130

Amounts repaid

(13,328

)

(13,699

)

Amounts written off

-

-

Amounts waived

-

-

Balance outstanding at end of year

334,175

323,762

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 20 July 2026 and were signed by:

Dr R C Swanton - Director